Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Senti Biosciences (SNTI) EBITDA Margin (2021 - 2023)

Senti Biosciences (SNTI) has 3 years of EBITDA Margin data on record, last reported at 5620.42% in Q4 2023.

  • For Q4 2023, EBITDA Margin rose 3648313.0% year-over-year to 5620.42%; the TTM value through Sep 2024 reached 21290.09%, up 2426697.0%, while the annual FY2023 figure was 3592.47%, 223435.0% down from the prior year.
  • EBITDA Margin reached 5620.42% in Q4 2023 per SNTI's latest filing, up from 4415.09% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 5620.42% in Q4 2023 and bottomed at 30862.71% in Q4 2022.
  • Average EBITDA Margin over 3 years is 4005.6%, with a median of 1076.41% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: crashed -2978631bps in 2022, then skyrocketed 3648313bps in 2023.
  • A 3-year view of EBITDA Margin shows it stood at 1076.41% in 2021, then tumbled by -2767bps to 30862.71% in 2022, then surged by 118bps to 5620.42% in 2023.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 5620.42% in Q4 2023, 4415.09% in Q3 2023, and 1995.73% in Q2 2023.